217 related articles for article (PubMed ID: 23092582)
1. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis.
Lee EY; Lee ZH; Song YW
Autoimmun Rev; 2013 Mar; 12(5):554-7. PubMed ID: 23092582
[TBL] [Abstract][Full Text] [Related]
2. CXCL10 and autoimmune diseases.
Lee EY; Lee ZH; Song YW
Autoimmun Rev; 2009 Mar; 8(5):379-83. PubMed ID: 19105984
[TBL] [Abstract][Full Text] [Related]
3. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.
Sucur A; Jajic Z; Artukovic M; Matijasevic MI; Anic B; Flegar D; Markotic A; Kelava T; Ivcevic S; Kovacic N; Katavic V; Grcevic D
Arthritis Res Ther; 2017 Jun; 19(1):142. PubMed ID: 28619088
[TBL] [Abstract][Full Text] [Related]
4. High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis.
Ruschpler P; Lorenz P; Eichler W; Koczan D; Hänel C; Scholz R; Melzer C; Thiesen HJ; Stiehl P
Arthritis Res Ther; 2003; 5(5):R241-52. PubMed ID: 12932287
[TBL] [Abstract][Full Text] [Related]
5. Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis.
Lee EY; Seo M; Juhnn YS; Kim JY; Hong YJ; Lee YJ; Lee EB; Song YW
Arthritis Res Ther; 2011 Jun; 13(3):R104. PubMed ID: 21708014
[TBL] [Abstract][Full Text] [Related]
6. JN-2, a C-X-C motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model.
Kim B; Lee JH; Jin WJ; Kim HH; Ha H; Lee ZH
Eur J Pharmacol; 2018 Mar; 823():1-10. PubMed ID: 29378189
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis.
Lee JH; Kim B; Jin WJ; Kim HH; Ha H; Lee ZH
Arthritis Res Ther; 2017 Jul; 19(1):163. PubMed ID: 28724396
[TBL] [Abstract][Full Text] [Related]
8. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.
Proost P; Struyf S; Loos T; Gouwy M; Schutyser E; Conings R; Ronsse I; Parmentier M; Grillet B; Opdenakker G; Balzarini J; Van Damme J
Arthritis Res Ther; 2006; 8(4):R107. PubMed ID: 16846531
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis.
Kang SE; Park JK; Yoo HJ; Kang HS; Park YW; Park BC; Park JE; Lee EY; Lee EB; Song YW
Transl Res; 2021 Jun; 232():75-87. PubMed ID: 33453429
[TBL] [Abstract][Full Text] [Related]
10. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A
Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456
[TBL] [Abstract][Full Text] [Related]
11. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis and the alpha-chemokine IP-10.
Di Domenicantonio A
Clin Ter; 2014; 165(6):e447-51. PubMed ID: 25524204
[TBL] [Abstract][Full Text] [Related]
13. Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA).
Aggarwal A; Agarwal S; Misra R
Clin Exp Immunol; 2007 Jun; 148(3):515-9. PubMed ID: 17374135
[TBL] [Abstract][Full Text] [Related]
14. [Treatment for rheumatoid arthritis by chemokine blockade].
Nanki T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):172-80. PubMed ID: 27320932
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus.
Henneken M; Dörner T; Burmester GR; Berek C
Arthritis Res Ther; 2005; 7(5):R1001-13. PubMed ID: 16207316
[TBL] [Abstract][Full Text] [Related]
16. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components.
Chen X; Oppenheim JJ; Howard OM
Cell Mol Immunol; 2004 Oct; 1(5):336-42. PubMed ID: 16285892
[TBL] [Abstract][Full Text] [Related]
17. Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells.
Endres M; Andreas K; Kalwitz G; Freymann U; Neumann K; Ringe J; Sittinger M; Häupl T; Kaps C
Osteoarthritis Cartilage; 2010 Nov; 18(11):1458-66. PubMed ID: 20709179
[TBL] [Abstract][Full Text] [Related]
18. Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis.
Broeren MG; de Vries M; Bennink MB; Arntz OJ; Blom AB; Koenders MI; van Lent PL; van der Kraan PM; van den Berg WB; van de Loo FA
Hum Gene Ther; 2016 Mar; 27(3):244-54. PubMed ID: 26711533
[TBL] [Abstract][Full Text] [Related]
19. [Inflammatory cytokines in rheumatoid arthritis].
Murakami M; Nishimoto N
Clin Calcium; 2012 Nov; 22(11):1737-46. PubMed ID: 23103817
[TBL] [Abstract][Full Text] [Related]
20. Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines.
van Roon JA; Bijlsma JW; Lafeber FP
Curr Opin Investig Drugs; 2002 Jul; 3(7):1011-6. PubMed ID: 12186260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
